• Bystander memory T cells and IMiD/checkpoint therapy in multiple myeloma: A dangerous tango? 

      Sponaas, Anne-Marit; Waage, Anders; Vandsemb, Esten; Misund, Kristine; Børset, Magne; Sundan, Anders; Slørdahl, Tobias Schmidt; Standal, Therese (Peer reviewed; Journal article, 2021)
      In this review article we discuss the role of the memory T cells in multiple myeloma (MM) and how they may influence immune responses in patients that received immunomodulating drugs and check point therapy
    • Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group 

      Gregersen, Henrik; Peceliunas, Valdas; Remes, Kari; Schjesvold, Fredrik Hellem; Abildgaard, Niels; Nahi, Hareth; Andersen, Niels Frost; Vangsted, Annette Juul; Klausen, Tobias Wirenfeldt; Helleberg, Carsten; Carlson, Kristina; Frølund, Ulf Christian; Axelsson, Per; Stromberg, Olga; Blimark, Cecilie Hveding; Crafoord, Jacob; Tsykunova, Galina; Eshoj, Henrik Rode; Waage, Anders; Hansson, Markus; Gulbrandsen, Nina (Peer reviewed; Journal article, 2021)
      Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and ...
    • Chemical, Physical and Biological Triggers of Evolutionary Sonserved Bcl-xL-Mediated Apoptosis 

      Ianevski, Aleksandr; Kulesskiy, Evgeny; Krpina, Klara; Lou, Guofeng; Aman, Yahyah; Bugai, Andrii; Aasumets, Koit; Akimov, Yevhen; Bulanova, Daria; Gildemann, Kiira; Arutyunyan, Albert F.; Susova, Olga Yu.; Zhuze, Alexei L.; Ji, Ping; Wang, Wei; Holien, Toril; Bugge, Marit; Zusinaite, Eva; Oksenych, Valentyn; Lysvand, Hilde; Gerhold, Joachim M.; Bjørås, Magnar; Johansen, Pål; Waage, Anders; Heckman, Caroline A.; Fang, Evandro Fei; Kainov, Denis (Journal article; Peer reviewed, 2020)
      Background: The evidence that pan-Bcl-2 or Bcl-xL-specific inhibitors prematurely kill virus-infected or RNA/DNA-transfected cells provides rationale for investigating these apoptotic inducers further. We hypothesized that ...
    • Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence 

      Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco M.; Rustad, Even Holth; Sanders, Mathijs A.; Rye, Morten Beck; Sponaas, Anne-Marit; van der Holt, Bronno; Zweegman, Sonja; Hovig, Eivind; Meza, Leonardo Zepeda; Sundan, Anders; Myklebost, Ola; Sonneveld, Pieter; Waage, Anders (Peer reviewed; Journal article, 2022)
      We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study before and after treatment. A change in clonal composition ...
    • Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival 

      Aass, Kristin Roseth; Nedal, Tonje Marie Vikene; Bouma, Siri Anshushaug; Tryggestad, Synne Stokke; Haukås, Einar; Slørdahl, Tobias Schmidt; Waage, Anders; Standal, Therese; Mjelle, Robin (Journal article; Peer reviewed, 2022)
    • Content of endothelial progenitor cells in autologous stem cellgrafts predict survival after transplantation for multiplemyeloma 

      Blix, Egil Støre; Kildal, Anders Benjamin; Bertelsen, Eirin Listau; Waage, Anders; Myklebust, June; Kolstad, Arne; Husebekk, Anne (Peer reviewed; Journal article, 2015)
      Multiple myeloma (MM) is considered an incurable B cell malignancy, although many patients can benefit from high-dose therapy with autologous stem cell transplantation (ASCT) as a first-line treatment. In non-Hodgkin ...
    • Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade 

      Yang, Rui; Elsaadi, Samah; Misund, Kristine; Abdollahi, Pegah; Vandsemb, Esten; Moen, Siv Helen; Kusnierczyk, Anna; Slupphaug, Geir; Standal, Therese; Waage, Anders; Slørdahl, Tobias Schmidt; Rø, Torstein Baade; Rustad, Even Holth; Sundan, Anders; Hay, Carl; Cooper, Zachary; Schuller, Alwin G.; Woessner, Richard; Borodowski, Alexandra; Menu, Eline; Børset, Magne; Sponaas, Anne-Marit (Peer reviewed; Journal article, 2020)
      Background PD1/PDL1-directed therapies have been unsuccessful for multiple myeloma (MM), an incurable cancer of plasma cells in the bone marrow (BM). Therefore, other immune checkpoints such as extracellular adenosine and ...
    • Germline variants at SOHLH2 influence multiple myeloma risk 

      Duran-Lozano, Laura; Thorleifsson, Gudmar; Lopez de Lapuente Portilla, Aitzkoa; Niroula, Abhishek; Went, Molly; Thodberg, Malte; Pertesi, Maroulio; Ajore, Ram; Cafaro, Caterina; Olason, P; Stefansdottir, Lilja; Bragi Walters, Walters; Halldorsson, Gisli H.; Turesson, Ingemar; Kaiser, Martin; Weinhold, Niels; Abildgaard, Niels; Andersen, Niels Frost; Mellqvist, Ulf-Henrik; Waage, Anders; Vangsted, Annette; Thorsteinsdottir, Unnur; Hansson, Markus; Houlston, Richard S.; Rafnar, Thorunn; Stefansson, Kari; Nilsson, Björn (Peer reviewed; Journal article, 2021)
      Multiple myeloma (MM) is caused by the uncontrolled, clonal expansion of plasma cells. While there is epidemiological evidence for inherited susceptibility, the molecular basis remains incompletely understood. We report a ...
    • Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study 

      Nielsen, Lene Kongsgaard; Stege, Claudia; Lissenberg-Witte, Birgit I.; van der Holt, Bronno; Mellqvist, Ulf-Henrik; Salomo, Morten; Bos, Gerard; Levin, Mark-David; Visser-Wisselaar, Heleen; Hansson, Markus; van der Velden, Annette W.G.; Deenik, Wendy; Coenen, Juleon; Hinge, Maja; Klein, Saskia K.; Tanis, Bea C.; Szatkowski, Damian Lukasz; Brouwer, Rolf E.; Westerman, Matthijs; Leys, Rineke; Sinnige, Harm A.M.; Haukås, Einar; van der Hem, Klaas G.; Durian, Marc F.; Gimsing, Peter; van de Donk, Niels; Sonneveld, Pieter; Waage, Anders; Abildgaard, Niels; Zweegman, Sonja (Peer reviewed; Journal article, 2019)
      Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ...
    • Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients 

      Rampa, Christoph Samuel; Tian, Erming; Våtsveen, Thea Kristin; Buene, Glenn; Slørdahl, Tobias Schmidt; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2014)
      Background Hepatocyte growth factor (HGF) is a pleiotropic cytokine which can lead to cancer cell proliferation, migration and metastasis. In multiple myeloma (MM) patients it is an abundant component of the bone marrow. ...
    • Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982–2017 

      Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2020)
      Population‐based studies from high‐quality nationwide cancer registries provide an important alternative to clinical trials in the assessment of the impact of modern myeloma treatment. Based on data from the Cancer Registry ...
    • Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells 

      Aass, Kristin Roseth; Mjelle, Robin; Kastnes, Martin Haugrud; Tryggestad, Synne Stokke; van den Brink, Luca M; Roseth, Ingrid Aass; Westhrin, Marita; Zahoor, Muhammad; Moen, Siv Helen; Nedal, Tonje Marie Vikene; Buene, Glenn; Misund, Kristine; Sponaas, Anne-Marit; Ma, Qianli; Sundan, Anders; Groen, Richard WJ; Slørdahl, Tobias Schmidt; Waage, Anders; Standal, Therese (Journal article; Peer reviewed, 2021)
      Interleukin-32 (IL-32) is a nonclassical cytokine expressed in cancers, inflammatory diseases, and infections. Its expression is regulated by two different oxygen sensing systems; HIF1α and cysteamine dioxygenase (ADO), ...
    • Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial 

      Sonja Zweegman, Zweegman; Claudia A M Stege, A; Haukås, Einar; Schjesvold, Fredrik H; Mark-David Levin, Levin; Waage, Anders; Rineke B L Leys, B; Saskia K Klein, K; Szatkowski, Damian Lukasz; Per Axelsson, Axelsson; Trung Hieu Do, Hieu; Dorota Knut-Bojanowska, Knut-Bojanowska; Ellen van der Spek, van; Asta Svirskaite, Svirskaite; Anja Klostergaard, Klostergaard; Morten Salomo, Salomo; Celine Blimark, Blimark; Paula F Ypma, F; Ulf-Henrik Mellqvist, Mellqvist; Pino J Poddighe, J; Marian Stevens-Kroef, Stevens-Kroef; Niels W C J van de Donk, W; Pieter Sonneveld, Sonneveld; Markus Hansson, Hansson; Bronno van der Holt, van; Niels Abildgaard, Abildgaard (Peer reviewed; Journal article, 2020)
    • Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial 

      Schmitz, Alexander; Brøndum, Rasmus Froberg; Johnsen, Hans Erik; Mellqvist, Ulf-Henrik; Waage, Anders; Gimsing, Peter; Op Bruinink, Davine Hofste; van der Velden, Vincent; van der Holt, Bronno; Hansson, Markus; Andersen, Niels Frost; Frølund, Ulf Christian; Helleberg, Carsten; Schjesvold, Fredrik Hellem; Ahlberg, Lucia; Gulbrandsen, Nina; Andreasson, Bjorn; Lauri, Birgitta; Haukås, Einar; Bødker, Julie Støve; Roug, Anne Stidsholt; Bøgsted, Martin; Severinsen, Marianne T.; Gregersen, Henrik; Abildgaard, Niels; Sonneveld, Pieter; Dybkær, Karen (Peer reviewed; Journal article, 2022)
      Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer ...
    • Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report 

      Murray, David L.; Puig, Noemi; Kristinsson, Sigurður Y.; Usmani, Saad; Dispenzieri, Angela; Bianchi, Giada; Kumar, Shaji; Chng, Wee Joo; Hajek, Roman; Paiva, Bruno; Waage, Anders; Rajkumar, S. Vincent; Durie, Brian (Peer reviewed; Journal article, 2021)
      Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect ...
    • Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines 

      Giliberto, Mariaserena; Miranda Santana, Leonardo; Holien, Toril; Misund, Kristine; Nakken, Sigve; Vodak, Daniel; Hovig, Eivind; Meza, Leonardo Zepeda; Coward, Eivind; Waage, Anders; Tasken, Kjetil; Skånland, Sigrid S (Peer reviewed; Journal article, 2022)
      Introduction: Multiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet ...
    • Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma 

      Aass, Kristin Roseth; Nedal, Tonje Marie Vikene; Tryggestad, Synne Stokke; Haukås, Einar; Slørdahl, Tobias Schmidt; Waage, Anders; Standal, Therese; Mjelle, Robin (Peer reviewed; Journal article, 2022)
      Multiple myeloma (MM) is an incurable cancer of terminally differentiated plasma cells that proliferate in the bone marrow. miRNAs are promising biomarkers for risk stratification in MM and several miRNAs are shown to have ...
    • Patterns of previous and secondary malignancies in patients with multiple myeloma 

      Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2021)
      Objectives: In contrast to secondary primary malignancies (SPM) following multiple myeloma (MM), less is known about previous malignancies. We therefore conducted a population-based study to assess the patterns of previous ...
    • Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia 

      Zatula, Alexey; Dikic, Aida; Mulder, Teska Celine; Sharma, Animesh; Vågbø, Cathrine Broberg; Sousa, Mirta; Waage, Anders; Slupphaug, Geir (Peer reviewed; Journal article, 2017)
      Plasma cell leukemia is a rare and aggressive plasma cell neoplasm that may either originate de novo (primary PCL) or by leukemic transformation of multiple myeloma (MM) to secondary PCL (sPCL). The prognosis of sPCL is ...
    • Risk of multiple myeloma and other malignancies among first- and second-degree relatives of patients with multiple myeloma: A population-based study 

      Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2022)
      Objectives We conducted a population-based study to assess the risk for multiple myeloma (MM) and other cancers in first- and second-degree relatives of MM patients, and to investigate whether evidence of anticipation is ...